Author

Ruey Pham

Institution: Tempus Labs (United States)

Observed institution: Tempus Labs (United States)

OpenAlex ID: A5114094907

376 Overcoming tumor heterogeneity – Clinical trial assays to prospectively assign patients customized multiplexed TCR-T cell therapy in Phase 1

2023 · Ribhu Nayar, Shazad A Khokhar, et al. · Journal for ImmunoTherapy of Cancer · 1

Works count: 1

Citation count: 1

H-index: 1

I10-index: